iPierian raises $30m to target tau, spin out complement program

South San Francisco-based iPierian raised $30m in private financing to prepare its monoclonal antibody targeting the tau protein for clinical development and to fund a series A round for the new company True North Therapeutics, which will develop iPierian's monoclonal antibody that selectively inhibits the classical complement pathway for the treatment of rare diseases.